On the stock market since 2013, it operates in the world of health and science. It has 68 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
There is $167.9M in the vault; even if every debt were paid off, $166.2M would remain.
The average analyst price target is $8.67 — 86% above today’s price.
A loss of $74.4M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
On our five-subject report card, RZLT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: RZLT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (32/100) says the stock isn’t cheap.